HC Wainwright Issues Pessimistic Estimate for SENS Earnings

Key Points

• HC Wainwright cut its SENS earnings forecasts, projecting a Q3 2026 loss of $0.58 per share versus $0.54 previously and a FY2026 loss of $2.41 per share. The firm still maintains a “Buy” rating and a $14 price target.
• Senseonics reported a quarterly loss of $0.63 per share, missing the $0.55 consensus estimate, on revenue of $14.48 million. The company remains deeply unprofitable, with a negative net margin of 225.09%.
• Analyst sentiment remains mixed but leans positive: four analysts rate the stock a Buy, one rates it Hold and one rates it Sell, producing a “Moderate Buy” consensus and an average target price of $17.20.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS - Free Report) - HC Wainwright dropped their Q3 2026 EPS estimates for shares of Senseonics Holdings, Inc. Common Stock in a report released on Friday, August 7th. HC Wainwright analyst S. Lee now forecasts that the company will earn ($0.58) per share for the quarter, down from their previous forecast of ($0.54). HC Wainwright currently has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for Senseonics Holdings, Inc. Common Stock's current full-year earnings is ($2.38) per share. HC Wainwright also issued estimates for Senseonics Holdings, Inc. Common Stock's Q4 2026 earnings at ($0.52) EPS, FY2026 earnings at ($2.41) EPS, Q1 2027 earnings at ($0.58) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.51) EPS, Q4 2027 earnings at ($0.40) EPS, FY2027 earnings at ($2.05) EPS, FY2028 earnings at ($1.60) EPS, FY2029 earnings at ($1.15) EPS and FY2030 earnings at ($0.60) EPS.

A number of other equities analysts also recently commented on SENS. Weiss Ratings upgraded shares of Senseonics Holdings, Inc. Common Stock from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, July 28th. Mizuho decreased their target price on Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an "outperform" rating for the company in a research report on Wednesday, July 15th. Wall Street Zen raised Senseonics Holdings, Inc. Common Stock from a "strong sell" rating to a "sell" rating in a research report on Saturday. Finally, Stifel Nicolaus decreased their price objective on Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a "hold" rating for the company in a report on Monday, May 11th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $17.20.

Senseonics Holdings, Inc. Common Stock Stock Performance

Shares of SENS stock opened at $7.54 on Tuesday. Senseonics Holdings, Inc. Common Stock has a 52-week low of $4.79 and a 52-week high of $11.58. The company has a debt-to-equity ratio of 0.62, a current ratio of 6.74 and a quick ratio of 6.40. The company has a market cap of $315.17 million, a price-to-earnings ratio of -3.38 and a beta of 1.01. The business's 50 day simple moving average is $5.87.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.08). The company had revenue of $14.48 million during the quarter. Senseonics Holdings, Inc. Common Stock had a negative net margin of 225.09% and a negative return on equity of 165.80%.

Institutional Trading of Senseonics Holdings, Inc. Common Stock

Hedge funds have recently modified their holdings of the stock. J.Safra Asset Management Corp acquired a new stake in shares of Senseonics Holdings, Inc. Common Stock during the 2nd quarter valued at about $636,000. Kestra Advisory Services LLC purchased a new position in Senseonics Holdings, Inc. Common Stock during the first quarter worth approximately $68,000. GSK plc acquired a new stake in Senseonics Holdings, Inc. Common Stock in the fourth quarter valued at approximately $60,000. State of Wyoming purchased a new stake in shares of Senseonics Holdings, Inc. Common Stock in the second quarter valued at approximately $67,000. Finally, Cetera Investment Advisers purchased a new stake in shares of Senseonics Holdings, Inc. Common Stock in the first quarter valued at approximately $85,000. Hedge funds and other institutional investors own 12.36% of the company's stock.

Senseonics Holdings, Inc. Common Stock News Summary

Here are the key news stories impacting Senseonics Holdings, Inc. Common Stock this week:

• Positive Sentiment: HC Wainwright continues to rate Senseonics “Buy” and retained its $14.00 target price, signaling confidence in the company’s long-term prospects despite ongoing losses.
• Neutral Sentiment: The analyst expects losses to narrow over time, forecasting EPS of ($2.05) in FY2027, ($1.60) in FY2028, ($1.15) in FY2029 and ($0.60) in FY2030. However, the company is still expected to remain unprofitable through FY2030.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS forecast to ($2.41) from ($2.23), compared with the current consensus estimate of ($2.38). It also lowered FY2027 EPS to ($2.05) from ($1.97), FY2028 to ($1.60) from ($1.57), FY2029 to ($1.15) from ($1.13), and FY2030 to ($0.60) from ($0.59).
• Negative Sentiment: Near-term quarterly forecasts were also cut: Q3 2026 EPS to ($0.58) from ($0.54), and Q4 2026 EPS to ($0.52) from ($0.48). These revisions point to deeper expected losses and may weigh on sentiment.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source